One Of The Cyclos Is A 1,2-thiazine (e.g.,1,2-benzothiazines, Etc.) Patents (Class 514/226.5)
  • Patent number: 11571428
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: August 3, 2021
    Date of Patent: February 7, 2023
    Assignee: AXSOME THERAPEUTICS, INC
    Inventor: Herriot Tabuteau
  • Patent number: 11331323
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: July 29, 2021
    Date of Patent: May 17, 2022
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 11083797
    Abstract: Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural).
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: August 10, 2021
    Assignee: Heron Therapeutics, Inc.
    Inventors: Thomas B. Ottoboni, Lee Ann Lynn Girotti
  • Patent number: 10987358
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: April 27, 2021
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 10807969
    Abstract: The meglumine salt of 1-(5,6-dichloro-1H-benzo[d]imidazol-2-yl)-1H-pyrazole-4-carboxylic acid (compound (1)) and pharmaceutically acceptable formulations thereof are described. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: October 20, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kia Sepassi, Michele C. Rizzolio
  • Patent number: 10696691
    Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: June 30, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Walter Vifian, Thomas Woltering
  • Patent number: 10688102
    Abstract: Disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: June 23, 2020
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 10668158
    Abstract: The present invention relates to a pharmaceutical composition containing a poorly soluble drug, hyaluronic acid, and a fatty acid, and to a method for preparing the same. The pharmaceutical composition of the present application has excellent stability even for long-term storage and allows a sustained release of the drug, thereby preventing an overdose of the drug and improving the therapeutic efficiency at an effected area.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: June 2, 2020
    Assignee: UNIVERSITY-INDUSTRY FOUNDATION, YONSEI UNIVERSITY
    Inventors: Jaemoon Yang, Jin-Suck Suh, Young Han Lee, Dan Heo
  • Patent number: 10463674
    Abstract: The present invention provides a process of manufacturing a sterile, ophthalmic pharmaceutical suspension comprising sterile active ingredient(s) such as sterile carbonic anhydrase inhibitors (CAIs) wherein the process does not involve the use of any special equipment's such as ball mill, milling bottle and/or jet mill The present process is simple, cost effective and efficient.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: November 5, 2019
    Assignee: Sentiss Pharma Private Limited
    Inventors: Mandar V. Shah, Deepak Bahri, Divya Pandit
  • Patent number: 10246468
    Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: April 2, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Walter Vifian, Thomas Woltering
  • Patent number: 10231924
    Abstract: A compounded topical composition may include an antiviral component, a topical base component, and a local anesthetic component. The antiviral component may include fine powder obtained by grinding oral tablets of one or more antiviral actives. The topical component may include the local anesthetic component. The local anesthetic component may be present in an amount between about 2% and about 8% by weight of the compounded topical composition and the antiviral component may be present in an amount between 4% and 12% by weight of the compounded topical composition. The antiviral component may include acyclovir, valaciclovir, penciclovir, famciclovir, or combinations thereof, and the topical base component may be a lidocaine topical, a lidocaine and prilocaine topical, or both.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: March 19, 2019
    Assignee: CMPD LICENSING, LLC
    Inventor: Jay Richard Ray, II
  • Patent number: 10098957
    Abstract: Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the “caine” classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural).
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: October 16, 2018
    Assignee: Heron Therapeutics, Inc.
    Inventors: Thomas B. Ottoboni, Lee Ann Lynn Girotti
  • Patent number: 9393314
    Abstract: Disclosed are meloxicam eye drops and the preparation method and use thereof. The eye drops contain active ingredient meloxicam or a pharmaceutically acceptable salt thereof, a solubilizer, a stabilizer, a pH adjusting agent, an antimicrobial agent and an osmotic pressure adjusting agent, wherein the solubilizer is one of hydroxypropyl-?-cyclodextrin, sulfobutylether-?-cyclodextrin, and ?-cyclodextrin or a mixture thereof, and the stabilizer is one of polymer povidone, sodium hyaluronate, and hypromellose or a mixture thereof.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: July 19, 2016
    Assignee: KANGYA OF NINGXIA PHARMACEUTICALS CO., LTD
    Inventors: Yajun Yang, Zhonggui He, Yimeng Qin
  • Patent number: 9149488
    Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and diethyl(2-cyanoethyl)phosphonate, or a pharmaceutically acceptable salt thereof. The present invention is directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering diethyl(2-cyanoethyl)phosphonate, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
    Type: Grant
    Filed: August 19, 2014
    Date of Patent: October 6, 2015
    Assignee: Olatec Industries LLC
    Inventors: Joseph P. St. Laurent, Gerald S. Jones, David M. Bresse, Scott A. Goodrich
  • Patent number: 9107888
    Abstract: An aqueous liquid bromfenac composition containing (a) bromfenac or a salt thereof and (b) benzalkonium chloride, characterized by that the composition has preservative efficacy and that the concentration of (b) benzalkonium chloride is higher than 0.0005% and lower than 0.005%.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: August 18, 2015
    Assignee: SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Shuichi Nishihata, Wakiko Asayama, Suzuka Iemoto
  • Patent number: 9101529
    Abstract: A plastic container containing a pharmaceutical composition comprising benzoic acid or a derivative or a pharmaceutically acceptable salt thereof and a COX-inhibitor of the oxicam-type or a pharmaceutical acceptable salt thereof, wherein the container material selected from one or more members of the group consisting of a homopolymer of polypropylene (PP), a copolymer of polypropylene (PP), a homopolymer of polyethylene terephthalate (PET) and a copolymer of polyethylene terephthalate (PET), and optionally one or more non-polymeric components.
    Type: Grant
    Filed: October 11, 2010
    Date of Patent: August 11, 2015
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Martin A. Folger, Samuel Crowley, Amy Wilson
  • Publication number: 20150148334
    Abstract: This invention provides compounds of formula I-A or I-B: wherein HY, G1, G2, R2, R12, W1, W2, n, and Ring A are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Application
    Filed: June 27, 2014
    Publication date: May 28, 2015
    Inventors: Brian S. Freeze, Masaaki Hirose, Hong Myung Lee, Todd B. Sells, Zhan Shi, Leo R. Takaoka, Stepan Vyskocil, Tianlin Xu
  • Publication number: 20150148305
    Abstract: The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously. The transdermal cream may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients. The transdermal cream may include lidocaine, prilocaine, meloxicam, and lamotrigine and/or topiramate. Alternatively, the transdermal cream may include a lidocaine/prilocaine base cream to which is added a fine powder of one or more ground up medications to form a compounded medication. The compounded medication in powder form may be generated from grinding up tablets of NSAIDs, anticonvulsants, nerve depressants, antidepressants, muscle relaxants, NMDA receptor antagonists, opiate or opioid agonists, and/or other agents. The compounded medication in powder form may include meloxicam, lamotrigine, topiramate, other active ingredients, and DMSO or Sterile Water for Irrigation.
    Type: Application
    Filed: January 29, 2015
    Publication date: May 28, 2015
    Inventors: Jay Richard Ray, II, Charles D. Hodges
  • Publication number: 20150141412
    Abstract: The invention refers to a process for preparing sterile active pharmaceutical ingredients (APIs) useful in the preparation of sterile product for ophthalmic use. The process comprises the gamma-ray sterilization treatment of the APIs powder in a protective atmosphere.
    Type: Application
    Filed: May 9, 2012
    Publication date: May 21, 2015
    Applicant: ICROM SpA
    Inventors: Mario Leone, Pierfrancesco Morosini
  • Publication number: 20150118229
    Abstract: The invention relates to the use of a JAK1 kinase-selective inhibitor that has minimal inhibitory activity towards Jak2 kinase for treating a disease, such as an inflammatory disease (e.g., moderate to severe Rheumatoid Arthritis) and/or bone loss, either alone or in combination with a DMARD (disease modifying anti-rheumatic drug), such as methotrexate. The invention also provides pharmaceutical composition, dosage formulation, administration route, and dosage schedule thereof.
    Type: Application
    Filed: October 24, 2014
    Publication date: April 30, 2015
    Applicant: ABBVIE INC.
    Inventors: Jeffrey W. Voss, Heidi S. Camp, Robert J. Padley
  • Publication number: 20150119386
    Abstract: The present invention relates to a process for preparing sterile ophthalmic suspension of carbonic anhydrase inhibitor. More particularly, the present invention relates to a process for preparing sterile ophthalmic suspension of brinzolamide.
    Type: Application
    Filed: May 21, 2013
    Publication date: April 30, 2015
    Inventors: Chandrasekhar Kadam, Jayant Karajgi, Sachin Jain, Ajay Mhaske, Sivakumaran Meenakshisunderam
  • Publication number: 20150111857
    Abstract: Compounds and compositions useful for treating disorders related to KIT and PDFGR are described herein.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Brian L. Hodous, Joseph L. Kim, Chandrasekhar V. Miduturu, Douglas Wilson, Yulian Zhang
  • Publication number: 20150111881
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound acyclovir and a therapeutically-effective amount of the COX-2 inhibitor meloxicam. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of acyclovir and meloxicam.
    Type: Application
    Filed: October 27, 2014
    Publication date: April 23, 2015
    Inventor: William L. Pridgen
  • Patent number: 8999938
    Abstract: The ophthalmic drug delivery vehicles provide comfort and compliance; drug solubility, residence time and permeability; and reduce side effects. In addition, the delivery vehicle can be slightly modified to provide an artificial tear formulation.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: April 7, 2015
    Assignee: GNT LLC
    Inventor: Gerald Horn
  • Publication number: 20150093338
    Abstract: There is provided compositions and methods for the treatment of respiratory conditions such as pulmonary hypertension and sickle-cell disease in a patient in need thereof. The composition and method are for treating a patient in need thereof by inhalation of a composition containing amino acid ester compounds comprising at least one nitric oxide releasing group and pharmaceutical salts thereof.
    Type: Application
    Filed: October 8, 2014
    Publication date: April 2, 2015
    Inventor: Michael Farber
  • Patent number: 8992980
    Abstract: Water soluble meloxicam granules comprising: (a) meloxicam; (b) a salt forming agent which forms the meglumine, sodium, potassium, or ammonium salt of meloxicam; (c) a binder; (d) a sugar or sweetener; and (e) a carrier, and optionally a flavoring agent and optionally other excipients, processes for preparing them and their use for treating respiratory or inflammatory complaints in mammals.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: March 31, 2015
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Stefan Henke, Martin Andreas Folger, Jens Schmalz, Diana Christine Keilhofer, Hans-Juergen Kroff, Nina Herz
  • Publication number: 20150080385
    Abstract: The present invention relates to a stable pharmaceutical formulation for topical administration containing a therapeutically effective quantity of Brinzolamide or ophthalmologic acceptable salts thereof and an effective quantity of a surfactant such as poloxamer, to be used for the treatment of ocular hypertension and glaucoma.
    Type: Application
    Filed: March 8, 2013
    Publication date: March 19, 2015
    Applicant: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Vasiliki Samara, Efstathia Milouli, Ioanna Kontiza, Ioanna Koutri
  • Publication number: 20150065431
    Abstract: The present invention provides methods of reducing cutaneous scar formation by treating a cutaneous wound with a composition comprising a therapeutic agent that is a sodium channel blocker and/or an inhibitor of the Nax/SCN7A pathway. The present invention also provides wound cover components impregnated with such compositions, kits composed of such compositions with a wound dressing or sterile wipe, and mixtures of such compositions with a topical component (e.g., cream, ointment, or gel) suitable for application to a cutaneous wound. The present invention also provides compositions, kits, devices, and methods for treating skin conditions (e.g., dermatitis, psoriasis, or other skin conditions) with such compositions and devices. Examples of such therapeutic agents include, but are not limited to, an inhibitor of a gene or protein selected from: ENac, COX-2, PGE2, PI3K, PKB, Nax Prss8, IL-1?, IL-8, SAPK, Erk gene, p38 gene, PAR2, S100A8, S100A9, S100A12.
    Type: Application
    Filed: August 27, 2014
    Publication date: March 5, 2015
    Inventors: Wei Xu, Seok Jong Hong, Robert D. Galiano, Thomas A. Mustoe
  • Publication number: 20150065493
    Abstract: Process of preparing sterile brinzolamide using ethylene-oxide gas sterilisation, sterile brinzolamide obtainable by said process and pharmaceutical compositions comprising said sterile brinzolamide.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 5, 2015
    Applicant: AZAD Pharmaceutical Ingredients AG
    Inventors: Van Van Khov-Tran, Frank Porstmann, Jan Ondracek, Gregory Grams
  • Publication number: 20150051198
    Abstract: An aqueous cyclodextrin-free solution of meloxicam suitable is provided for administration by needleless injection, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients.
    Type: Application
    Filed: October 29, 2014
    Publication date: February 19, 2015
    Inventors: Martin A. Folger, Stefan Henke, Bernhard Hassel, Bernd Zierenberg
  • Publication number: 20150050355
    Abstract: A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAECD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.
    Type: Application
    Filed: September 17, 2014
    Publication date: February 19, 2015
    Inventors: James D. Pipkin, Gerold L. Mosher, Douglas B. Hecker
  • Patent number: 8940271
    Abstract: The invention includes compositions for transmucosal administration to an animal comprising at least one active agent and a pharmaceutically acceptable carrier. A preferred active agent is selected from the group consisting of meloxicam, carprofen, enrofloxacin, clemastine, diphenhydramine, digoxin, levothyroxine, cyclosporine, ondansetron, lysine, zolpidem, propofol, nitenpyram, ivermectin, milbemycin, and pharmaceutically acceptable salts, solvates and esters thereof. In another embodiment, the invention includes methods of treating or preventing a condition in an animal comprising transmucosally administering a composition comprising a therapeutically or prophylactically effective amount of an active agent and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: January 27, 2015
    Assignee: Abbott Laboratories
    Inventors: Mark C. Heit, Antonio M. Benitz, Dennis F. Steadman, David M. Petrick
  • Publication number: 20150011538
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound valaciclovir and a therapeutically-effective amount of the COX-2 inhibitor meloxicam. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of valaciclovir and meloxicam.
    Type: Application
    Filed: September 23, 2014
    Publication date: January 8, 2015
    Inventor: William L. Pridgen
  • Patent number: 8920820
    Abstract: An aqueous cyclodextrin-free solution of meloxicam suitable is provided for administration by needleless injection, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: December 30, 2014
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Martin A. Folger, Stefan Henke, Bernhard Hassel, Bernd Zierenberg
  • Publication number: 20140378391
    Abstract: The ophthalmic drug delivery vehicles provide comfort and compliance; drug solubility, residence time and permeability; and reduce side effects. In addition, the delivery vehicle can be slightly modified to provide an artificial tear formulation.
    Type: Application
    Filed: June 21, 2013
    Publication date: December 25, 2014
    Inventor: Gerald Horn
  • Publication number: 20140374516
    Abstract: Disclosed is a process for the preparation of drug/carrier inclusion composites which involves co-grinding the mixture of drug and carrier powders in a fluid-jet mill, in particular one using air or nitrogen as the fluid, which is suitably modified to allow mechanical fusion of the powders.
    Type: Application
    Filed: January 25, 2013
    Publication date: December 25, 2014
    Applicant: MICRO-MACINAZIONE S.A.
    Inventors: Fabio Carli, Piero Iamartino, Milko Leone
  • Publication number: 20140378401
    Abstract: The ophthalmic drug delivery vehicles provide comfort and compliance; drug solubility, residence time and permeability; and reduce side effects. In addition, the delivery vehicle can be slightly modified to provide an artificial tear formulation.
    Type: Application
    Filed: December 18, 2013
    Publication date: December 25, 2014
    Applicant: GNT, LLC
    Inventor: Gerald Horn
  • Publication number: 20140378415
    Abstract: The present invention provides compounds of formula (I) wherein P is P0, heterocyclyl or heterocyclyl substituted by one to five Z formula (II); Y1, Y2, Y3 and Y4 are independently of each other C—H, C—R5, or nitrogen; G1 is oxygen or sulfur; X4 is C1-C8 haloalkyl; R4 is aryl or aryl substituted by one to five R9, or heteroaryl or heteroaryl substituted by one to five R9; and R1, R2, R4, R5, R9 and Z are as defined in the claims. The invention also provides compositions comprising the compounds of formula (I), intermediates useful in the preparation of compounds of formula (I) and methods of using the compounds of formula (I) to control insects, acarines, nematodes or molluscs.
    Type: Application
    Filed: August 27, 2012
    Publication date: December 25, 2014
    Applicant: SYNGENTA PARTICIPATIONS AG
    Inventors: Jerome Yves Cassayre, Myriem El Qacemi
  • Publication number: 20140364384
    Abstract: The present invention relates to the detection of markers in exhaled breath, wherein the detection of the presence or absence of the marker(s) in exhaled breath is used to assess various clinical data, including patient adherence in taking the medication and patient enzymatic (metabolic) competence in metabolizing the medication. An embodiment of the invention comprises a parent therapeutic agent labeled with a marker, where upon metabolism (e.g., via enzymatic action) of the therapeutic agent, the marker becomes volatile or semi-volatile and is present in the breath. In certain related embodiments, the marker contain a deuterium label, which is also present in the breath upon metabolism of the therapeutic agent. In another embodiment of the invention, the therapeutic agent is associated with a taggant (that may be either labeled or unlabeled with deuterium), which in turn will generate a marker in the breath that is easily measurable.
    Type: Application
    Filed: April 23, 2014
    Publication date: December 11, 2014
    Applicant: University of Florida Research Foundation, Inc.
    Inventors: Richard J. Melker, Donn Michael Dennis, Christopher D. Batich, Mark S. Gold
  • Publication number: 20140336163
    Abstract: The invention relates to injectable pharmaceutical compositions, methods of use and formulation, wherein the compositions comprise: one or more water soluble complexes, each complex comprising a cyclodextrin or a cyclodextrin derivative and a hydrophobic drug; at least one preservative; and at least one co-solvent. The compositions are effectively preserved in accordance with the European Pharmacopoeia 2011 Test for Efficacy of Antimicrobial Preservation, satisfying at least the B criteria as it applies to parenterals, and the United States Pharmacopeia 2011 Guidelines for Antimicrobial Effectiveness Testing, satisfying the criteria for Category 1 (injectable) products.
    Type: Application
    Filed: November 27, 2012
    Publication date: November 13, 2014
    Inventors: Kirby Shawn Pasloske, Kai Lau, Sarah Jane Richardson, Amanda Aileen Willis
  • Publication number: 20140332438
    Abstract: A method of treating animals includes administering water soluble granules to an animal, where the water soluble granules include meloxicam, salt forming agent operable to form a meloxicam salt, a binder, and a carrier.
    Type: Application
    Filed: July 28, 2014
    Publication date: November 13, 2014
    Applicant: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Stefan Henke, Martin A. Folger, Jens Lehmann, Diana C. Keilhofer, Hans-Juergen Kroff, Nina Herz
  • Publication number: 20140314827
    Abstract: Described herein are compositions comprising at least one buffering agent, at least one chelating agent and at least one antimicrobial agent, which can be used for treating and/or preventing diseases or disorders in a variety of animals. In certain embodiments, in particular, the compositions can be used for treating and/or preventing ophthalmic and oral cavity diseases or disorders in dogs and cats and oropharyngeal and/or guttural pouch diseases or disorders in equines. In certain embodiments, the compositions can also be used for treating ophthalmic or oral cavity diseases or disorders in humans.
    Type: Application
    Filed: April 17, 2014
    Publication date: October 23, 2014
    Inventor: Steven A. Melman
  • Publication number: 20140296140
    Abstract: An equipment assembly for preparing, harvesting and collecting particles is disclosed. The assembly comprises a tandem filter system with one or more high pressure filters, one or more low pressure filters and one or more collection vessel. Particles can be prepared, harvested and collected continuously, semi-continuously or in a batch-type operation. A tandem filter system and its method of use are also disclosed. Particles made with the assembly and according the instant methods are also disclosed. The assembly provides improved particle harvesting and collection over other systems and permits continuous particle formation, in particular by dispersion of a solute-containing process fluid within a supercritical anti-solvent.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 2, 2014
    Applicant: CRITITECH, INC.
    Inventors: Greg S. JOHNSON, Bala SUBRAMANIAM, Fenghui Niu
  • Publication number: 20140296191
    Abstract: The present invention relates to pharmaceutical compositions of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle or as a solvent system in preparation of such pharmaceutical compositions. The pharmaceutical compositions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formulations containing such pharmaceutical actives and are suitable for use as injectables for intravenous and intramuscular administration, as well as for use as a preformed solution/liquid for filling in and preparation of capsules, tablets, nasal sprays, gargles, dermal applications, gels, topicals, liquid oral dosage forms and other dosage forms.
    Type: Application
    Filed: April 2, 2014
    Publication date: October 2, 2014
    Applicant: THEMIS MEDICARE LIMITED
    Inventors: Dinesh Shantilal PATEL, Sachin Dinesh PATEL, Shashikant Prabhudas KURANI, Madhavlal Govindlal PATEL
  • Publication number: 20140287048
    Abstract: An oral paste comprising: (i) at least one non-steroidal anti-inflammatory drug; (ii) at least one viscosity modifying agent; and (iii) a liquid vehicle.
    Type: Application
    Filed: October 16, 2012
    Publication date: September 25, 2014
    Applicant: NORBROOK LABORATORIES LIMITED
    Inventors: Louise Reynolds, William Blakely, Manish Umrethia
  • Publication number: 20140275046
    Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Heron Therapeutics, Inc.
    Inventors: Thomas B. Ottoboni, Lee Ann Lynn Schillinger, Joseph Niemann
  • Patent number: 8822457
    Abstract: This application discloses 5-phenyl-1H-pyridin-2-one and 6-phenyl-2H-pyridazin-3-one derivatives according to generic Formulae I-IV: wherein, variables R, X, Y1, Y2, Y2?, Y3, Y4, n and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions comprising compounds of Formulae I-IV and at least one carrier, diluent or excipient.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: September 2, 2014
    Assignee: Roche Palo Alto LLC
    Inventors: Nolan James Dewdney, Rama K. Kondru, Bradley E. Loe, Yan Lou, Joel McIntosh, Timothy D. Owens, Michael Soth
  • Patent number: 8796264
    Abstract: The present invention relates to new 2-piperazin-1-yl-4H-1,3-benzothiazin-4-one derivatives and their use for the treatment of mammalian infections caused by bacteria, especially diseases like tuberculosis (TB), Buruli ulcer and leprosy that result from infection with closely related mycobacteria.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: August 5, 2014
    Assignee: Ecole Polytechnique Federale de Lausanne (EPFL)
    Inventors: Vadim Makarov, Stewart Cole
  • Patent number: 8791105
    Abstract: Methods of improving performance, increasing weight gain, and decreasing incidence of disease in ruminant and pre-ruminant animals, such as cattle, after undergoing painful processing procedures, such as castration and dehorning, are provided. Veterinary formulations for use in methods of the invention are also provided. The formulations comprise a compound selected from the group consisting of meloxicam, gabapentin, the pharmaceutically acceptable salts thereof, and combinations thereof. Methods of treating pathological pain in cattle are also provided.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: July 29, 2014
    Assignee: Kansas State University Research Foundation
    Inventors: Johann F. Coetzee, Stanley P. Kukanich
  • Publication number: 20140206606
    Abstract: The present invention provides compounds of formula (I), wherein G1 is oxygen; R1 is hydrogen; R2 is group P (P) L is a bond, methylene or ethylene; one of A1 and A2 is S, SO or SO2 and the other is —C(R4)R4—R3 is hydrogen or methyl; each R4 is independently hydrogen or methyl; Y1 is C—R6, CH or nitrogen; Y2 and Y3 are independently CH or nitrogen; wherein no more than two of Y1, Y2 and Y3 are nitrogen and wherein Y2 and Y3 are not both nitrogen; R5 is hydrogen, halogen, cyano, nitro, NH2, C1-C2alkyl, C1-C2haloalkyl, C3-C5cycloalkyl, C3-C5halocycloalkyl, C1-C2alkoxy, C1-C2haloalkoxy; R6 together with R5 forms a —CH?CH—CH?CH— bridge; X2 is C—X6 or nitrogen; X1, X3 and X6 are independently hydrogen, halogen or trihalomethyl, wherein at least two of X1, X3 and X6 are not hydrogen; X4 is trifluoromethyl, difluoromethyl or chlorodifluoromethyl.
    Type: Application
    Filed: August 24, 2012
    Publication date: July 24, 2014
    Applicant: SYNGENTA PARTICIPATIONS AG
    Inventors: Jerome Yves Cassayre, Peter Renold, Thomas Pitterna, Myriem El Qacemi